Current Neurology and Neuroscience Reports

, Volume 6, Issue 4, pp 295–301

Preclinical diagnosis of parkinson’s disease: Are we there yet?



Preclinical Parkinson’s disease (PD) can be defined as a state that precedes the diagnosis of PD but without the presence of the characteristic motor features of the disorder. In such a situation, subtle non-motor features may be present or subclinical abnormalities may exist that can be detected only by physiologic testing. Alternatively, lifelong traits such as genetic mutations may predict the onset of PD in the absence of any clinical or physiologic abnormalities. A number of diagnostic technologies are currently available that can detect both preclinical states and traits that will lead to PD in the future. The current challenges are to refine these technologies and to determine how they should be employed so that their use is ethical, practical, and meaningful to at-risk individuals.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Polymeropoulos MH, Lavedan C, Leroy E, et al.: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276:2045–2047.PubMedCrossRefGoogle Scholar
  2. 2.
    Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews [see comment]. N Engl J Med 2004, 351:1972–1977.PubMedCrossRefGoogle Scholar
  3. 3.
    Lucking CB, Durr A, Bonifati V, et al.: Association between early-onset Parkinson’s Disease and mutations in the parkin gene. N Engl J Med 2000, 342:1560–1567.PubMedCrossRefGoogle Scholar
  4. 4.
    Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 2005, 365:410–411.Google Scholar
  5. 5.
    Piccini P, Burn DJ, Ceravolo R, et al.: The role of inheritance in sporadic Parkinson’s Disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999, 45:577–582.PubMedCrossRefGoogle Scholar
  6. 6.
    Marek KL, Seibyl JP, Zoghbi SS, et al.: [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996, 46:231–237.PubMedGoogle Scholar
  7. 7.
    Montgomery EB, Baker KB, Lyons K, Koller WC: Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology 1999, 52:757–762.PubMedGoogle Scholar
  8. 8.
    Ponsen MM, Stoffers D, Booij J, et al.: Idiopathic Hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004, 56:173–181. This study describes the prospective identification of individuals with preclinical PD. At-risk individuals were first identified using a combination of olfactory testing and SPECT imaging and then followed prospectively to determine if they developed clinical PD.PubMedCrossRefGoogle Scholar
  9. 9.
    Stern MB: The preclinical detection of Parkinson’s disease: ready for prime time? Ann Neurol 2004, 56:169–171.PubMedCrossRefGoogle Scholar
  10. 10.
    Armstrong K, Calzone K, Stopfer J, et al.: Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prevention 2000, 9:1251–1254.Google Scholar
  11. 11.
    Quaid KA, Morris M: Reluctance to undergo predictive testing - the case of Huntington disease. Am J Med Genet 1993, 45:41–45.CrossRefGoogle Scholar
  12. 12.
    Parkinson Study Group: A controlled, randomized, delayed-start study of rasagilinie in early Parkinson’s disease. Arch Neurol 2004, 61:561–566.Google Scholar
  13. 13.
    Ravina BM, Fagan SC, Hart RG, et al.: Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology 2003, 60:1234–1240. This is a systematic review of compounds with potential neuroprotective properties. The paper describes the preclinical and clinical evidence for efficacy.PubMedGoogle Scholar
  14. 14.
    Shults CW, Oakes D, Kieburtz K, et al.: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002, 59:1541–1550.PubMedCrossRefGoogle Scholar
  15. 15.
    Lang AE, Gill SS, Patel NK, et al.: Randomized, controlled trial of intraputamenal GDNF infusion in Parkinson’s disease. Ann Neurol 2006, 59:459–466.PubMedCrossRefGoogle Scholar
  16. 16.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181–184.PubMedGoogle Scholar
  17. 17.
    Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Archives of Neurology 1999, 56:33–39.PubMedCrossRefGoogle Scholar
  18. 18.
    Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303–308.PubMedCrossRefGoogle Scholar
  19. 19.
    Morrish PK, Sawle GV, Brooks DJ: The rate of progression of Parkinson’s disease. A longitudinal [18F]DOPA PET study. Adv Neurol 1996, 69:427–431.PubMedGoogle Scholar
  20. 20.
    Marek KL, Seibyl JP, Zoghbi SS, et al.: [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 1996, 46:231–237.PubMedGoogle Scholar
  21. 21.
    Dekker MC, Bonifati V, van Duijn CM: Parkinson’s disease: piecing together a genetic jigsaw. Brain 2003, 126(Pt 8):1722–1733.PubMedCrossRefGoogle Scholar
  22. 22.
    Braak H, Del Tredici K, Rub U, et al.: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24:197–211. This paper describes a staging system for Lewy body pathology. The authors suggest that the earliest pathology in PD may not be in the substantia nigra.PubMedCrossRefGoogle Scholar
  23. 23.
    Piccini P, Burn DJ, Ceravolo R, et al.: The role of inheritance in sporadic Parkinson’s Disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999, 45:577–582.PubMedCrossRefGoogle Scholar
  24. 24.
    Jennings DL, Seibyl JP, Oakes D, et al.: (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004, 61:1224–1229.PubMedCrossRefGoogle Scholar
  25. 25.
    Mozley PD, Schneider JS, Acton PD, et al.: Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000, 41:584–589.PubMedGoogle Scholar
  26. 26.
    Chou KL, Hurtig HI, Stern MB, et al.: Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism Related Disord 2004, 10:375–379.CrossRefGoogle Scholar
  27. 27.
    Becker G, Seufert J, Bogdahn U, et al.: Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 1995, 45:182–184.PubMedGoogle Scholar
  28. 28.
    Berg D, Siefker C, Becker G: Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 2001, 248:684–689. This is the first report of abnormal transcranial sonography in PD.PubMedCrossRefGoogle Scholar
  29. 29.
    Walter U, Niehaus L, Probst T, et al.: Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 2003, 60:74–77.PubMedCrossRefGoogle Scholar
  30. 30.
    Berg D, Roggendorf W, Schroder U, et al.: Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002, 59:999–1005.PubMedCrossRefGoogle Scholar
  31. 31.
    Ruprecht-Dorfier P, Berg D, Tucha O, et al.: Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 2003, 18:416–422.CrossRefGoogle Scholar
  32. 32.
    Braune S, Reinhardt M, Bathmann J, et al.: Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson’s disease with autonomic failure. Acta Neurol Scand 1998, 97:307–314.PubMedGoogle Scholar
  33. 33.
    Braune S, Reinhardt M, Schnitzer R, et al.: Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999, 53:1020–1025.PubMedGoogle Scholar
  34. 34.
    Yoshita M: Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998, 155:60–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Courbon F, Brefel-Courbon C, Thalamas C, et al.: Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 2003, 18:890–897.PubMedCrossRefGoogle Scholar
  36. 36.
    Muller A, Reichmann H, Livermore A, Hummel T: Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and longterm follow-up of de-novo IPD patients. J Neural Transm 2002, 109:805–811.PubMedCrossRefGoogle Scholar
  37. 37.
    Doty RL, Deems DA, Stellar S: Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988, 38:1237–1244.PubMedGoogle Scholar
  38. 38.
    Doty RL, Golbe LI, McKeown DA, et al.: Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology 1993, 43:962–965.PubMedGoogle Scholar
  39. 39.
    Stern MB, Doty RL, Dotti M, et al.: Olfactory function in Parkinson’s disease subtypes. Neurology 1994, 44:266–268.PubMedGoogle Scholar
  40. 40.
    Khan NL, Katzenschlager R, Watt H, et al.: Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004, 62:1224–1226.PubMedGoogle Scholar
  41. 41.
    Doty RL, Shaman P, Dann M: Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984, 32:489–502.PubMedCrossRefGoogle Scholar
  42. 42.
    Doty RL, Bromley SM, Stern MB: Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurodegeneration 1995, 4:93–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Siderowf A, Newberg AB, Chou KL, et al.: TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson’s disease. Neurology 2005, 64:1716–1720.PubMedCrossRefGoogle Scholar
  44. 44.
    Weintraub D, Moberg PJ, Duda JE, et al.: Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc 2004, 52:784–788.PubMedCrossRefGoogle Scholar
  45. 45.
    Menza MA, Mark MH, Burn DJ, Brooks DJ: Personalitycorrelates of [F-18] dopa striatal uptake—results of positron-emission tomography in Parkinsons disease. J Neuropsychiatry Clin Neurosci 1995, 7:176–179.PubMedGoogle Scholar
  46. 46.
    Glosser G, Clark C, Freundlich B, et al.: Controlled investigation of current and premorbid personality: characteristics of Parkinson’s disease patients. Mov Disord 1995, 10:201–206.PubMedCrossRefGoogle Scholar
  47. 47.
    Hubble JP, Venkatesh R, Hassanein RE, et al.: Personality and depression in Parkinson’s disease. J Nervous Mental Dis 1993, 181:657–662.CrossRefGoogle Scholar
  48. 48.
    Leentjens AF, Van den AkkerM, Metsemakers JF, et al.: Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 2003, 18:414–418.PubMedCrossRefGoogle Scholar
  49. 49.
    Shiba M, Bower JH, Maraganore DM, et al.: Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord 2000, 15:669–677.PubMedCrossRefGoogle Scholar
  50. 50.
    Gonera EG, van HofM, Berger HJ, et al.: Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997, 12:871–876.PubMedCrossRefGoogle Scholar
  51. 51.
    Schenck CH, Bundlie SR, Mahowald MW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388–393.PubMedGoogle Scholar
  52. 52.
    Eisensehr I, Linke R, Noachtar S, et al.: Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain 2000, 123:1155–1160.PubMedCrossRefGoogle Scholar
  53. 53.
    Plazzi G, Cortelli P, Montagna P, et al.: REM sleep behaviour disorder differentiates pure autonomic failure from multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry 1998, 64:683–685.PubMedCrossRefGoogle Scholar
  54. 54.
    Kessler S, Field T, Worth L, Mosbarger H: Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet 1987, 26:259–270.PubMedCrossRefGoogle Scholar
  55. 55.
    Markel DS, Young AB, Penney JB: At-risk persons’ attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. Am J Med Genet 1987, 26:295–305.PubMedCrossRefGoogle Scholar
  56. 56.
    Mastromauro C, Myers RH, Berkman B: Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet 1987, 26:271–282.PubMedCrossRefGoogle Scholar
  57. 57.
    Babul R, Adam S, Kremer B, et al.: Attitudes toward direct predictive testing for the huntington disease gene—relevance for other adult-onset disorders. JAMA 1993, 270:2321–2325.PubMedCrossRefGoogle Scholar
  58. 58.
    Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993, 328:176–183.Google Scholar
  59. 59.
    McKinnon WC, Baty BJ, Bennett RL, et al.: Predisposition genetic testing for late-onset disorders in adults—a position paper of the National Society of Genetic Counselors. JAMA 1997, 278:1217–1220.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Parkinson’s Disease and Movement Disorders Center, Department of NeurologyUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations